Trial of Rehabilitation in Phase 1 After Coronary Artery Bypass Grafting
Launched by RIGSHOSPITALET, DENMARK · Sep 11, 2013
Trial Information
Current as of July 21, 2025
Completed
Keywords
ClinConnect Summary
The explorative outcome measures consist of two parts: physical capacity and mental and physical health. Physical capacity is measured by peak VO2 max and 6 minutes' walk test at discharge and 4 weeks following surgery. Perceived mental and physical health is measured by the Medical Outcome Study Short Form 36 (SF-36) at admission, discharge and 4 weeks following surgery. Furthermore questionnaires measuring anxiety and depression (Hospital Anxiety and Depression Scale), health-related quality of life (HeartQoL), fatigue (MFI-20) cognitive and emotional representation of illness (B-IPQ), ph...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 18 years or older.
- • Persons with ischaemic heart disease referred to elective coronary artery bypass graft surgery.
- • Speaks and understands Danish.
- • Provide written informed consent.
- Exclusion Criteria:
- • Patients at intermediate or high risk according to their cardiovascular status
- • Patients with illness limiting the ability to exercise.
- • Patients without permanent residence.
About Rigshospitalet, Denmark
Rigshospitalet, located in Copenhagen, Denmark, is one of the leading hospitals in Scandinavia and a prominent center for clinical research and innovation. As a key academic institution affiliated with the University of Copenhagen, Rigshospitalet is dedicated to advancing healthcare through rigorous clinical trials and groundbreaking research across various medical disciplines. The hospital’s commitment to excellence is reflected in its multidisciplinary approach, collaboration with international research networks, and focus on improving patient outcomes through evidence-based practices. With state-of-the-art facilities and a team of highly qualified professionals, Rigshospitalet plays a crucial role in translating scientific discoveries into effective treatments and therapies.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Copenhagen, , Denmark
Copenhagen, , Denmark
Patients applied
Trial Officials
Selina K Berg, PhD, Post doc
Principal Investigator
Rigshospitalet, Denmark
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials